Korean Post-marketing Surveillance Vyndamax® Capsules for the Treatment of Transthyretin Amyloid Cardiomyopathy

Study Summary

This non-interventioal study will be performed by design of post-marketing surveillance (PMS) as an additional pharmacovigilance activity of the Risk Management Plan (RMP) for Vyndamax® Capsules, which is required by the Ministry of Food and Drug Safety (MFDS) according to the local regulation. This post-marketing surveillance will investigate the safety and effectiveness of Vyndamax® Capsules as the treatment of transthyretin amyloid cardiomyopathy during 10 years under the setting of routine practice in Korea.

Conditions

ATTR-CM (Transthyretin Amyloid Cardiomyopathy)

Interventions / Drugs

Vyndamax (tafamidis 61mg)

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment110 participants

Primary Completion—

Lead SponsorPfizer

Data Retrieved2026-04-11 02:55:53.191170+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.